UNIVERSITY OF NEVADA, RENO

Sarcomatrix Advances S-969 Toward First-in-Human Dosing With SarcoVista Modeling and Expanded CMC Package

- Sarcomatrix Therapeutics is applying its proprietary SarcoVista translational modeling platform to select the starting dose and escalation design for the planned Phase 1 study of S-969. - S-969 is an oral, once-daily small molecule directed at alpha-7 beta-1 integrin, developed mutation-agnostically for Duchenne, Becker and limb-girdle muscular dystrophy type 2I/R9. - The company selected a sulfate salt form for S-969 and contracted drug substance and drug product manufacturers to supply toxicology and first-in-human material. - Sarcomatrix has engaged Duck Flats Pharma for integrated regulatory and nonclinical review, with two-species GLP toxicology identified as the rate-limiting step before a clinical trial application.